158
Controversias en medicina interna. Síndrome metabólico (Capítulo 12)
26. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003;289:2560–2572. 27. De la Sierra A, Gorostidi M, Marín R et al.: Evaluación y tratamiento de la hipertensión arterial en España. Documento de consenso. Med Clin (Barc) 2008;131:104–118. 28. American Diabetes Association: Standards of medical care in diabetes 2010. Diabetes Care 2010;33(Suppl 1):S11–S61. 29. JATOS Study Group: Principal results of the Japanese Trial to Assess Optimal Systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res 2008;31:2115–27. 30. The Telmisartan Randomized Assessment Study in ACE intolerant subjects with cardiovascular disease (TRANSCEND investigators): Effects of the angiotensin–receptor blocker telmisartan on cardiovascular events in high–risk patients intolerant to angiotensin–converting enzyme inhibitors: a randomized controlled trial. Lancet 2008;372:1174–1183. 31. The ACCORD Study Group: Effects of intensive blood–pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575–1585. 32. The NAVIGATOR Study Group: Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010. 33. Lewis E, Hunsicker L, Bain R et al.: The effect of angiotensin–converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456–1462. 34. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA et al., collaborative study group: Renoprotective effect of the angiotensin–receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–860. 35. Atkins RC, Briganti EM, Lewis JB, Hunsicker LG, Braden G et al.: Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005;45:281–287. 36. Brakis GL, Weir MR, Shanifar S, Zhang Z, Douglas J et al., RENAAL study group: Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003;163:1555–1565. 37. Bjork S, Mulec H, Johnsen SA, Norden G, Aurell M: Renal protective effect of enalapril in diabetic nephropathy. Br Med J 1992;304:339–343. 38. Mulec H, Johnsen SA, Bjork S: Long–term enalapril treatment in diabetic nephropathy. Kidney Int 1994;Suppl 45:S141–144. 39. Ruggenenti P, Fassi A, Ilieva AP et al. for the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators: Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941–51. 40. Heart Outcomes prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular outcome on people with diabetes mellitus: results in the HOPE study and micro–HOPE study. Lancet 2000;355:253–259. 41. Parving HH, Lehnert H, Bröchner–Mortensen J et al.: For the Irbesartan in patients with type 2 diabetes and microalbuminuria study group. N Engl J Med 2001;345:870–878. 42. Viberti G, Wheeldon NM for the MicroAlbuminuria Reduction with Valsartan (MARVAL) Study investigators: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure–independent effect. Circulation 2002;106:672–678. 43. Barnnet AH, Brain SC, Bouter P, Karlberg B, Madsbad S et al., diabetics exposed to telmisartan and enalapril study group: Angiotensin–receptor blockade versus converting enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;35:1952–1961. 44. Keane W, Brenner B, De Zeeuw D: The risk of developing end–stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study. Kidney Int 2003;63:1499.